Hyperfine (NASDAQ:HYPR) reported Q2 2025 GAAP revenue of $2.7 million, below estimates and a 25.7% decline from Q2 2024. However, GAAP earnings per share of $0.12 exceeded expectations, showing improvement from the previous quarter. Gross margin rose to 49.3%, driven by increased sales volume. The company focuses on portable MRI technology and aims to expand into international markets. Hyperfine also achieved FDA clearance for its Optive AI software and a new Swoop system. Financially, it narrowed its net loss and maintained prudent spending. Management reaffirmed revenue growth guidance for FY2025 and aims to surpass a 50% gross margin in the future.

Read more at Nasdaq: Hyperfine Posts Higher Margin in Q2